Humacyte names Carrie Cox CEO; Competitor sues Medtronic for alleged phony recall;

> Humacyte has named Carrie Cox as CEO. Humacyte release

> Medtronic sabotaged a competitor by engineering a phony product recall so Medtronic could monopolize the market in bone mills used in spinal fusion surgery, Lenox MacLaren Surgical Corp. claims in a federal antitrust complaint. Report

> While many college students hope to find a job with any company upon graduation these days, a second-year Case Western Reserve University medical student has already raised $100,000 for his own medical device start-up. Story

> Medical contract manufacturer and injection molder Pacific Plastics & Engineering has added an eighth clean room to its 21,000 square foot manufacturing plant in Soquel, CA, six miles south of Santa Cruz. The privately owned, 21-year-old company works both with companies in the stealth modes and larger healthcare companies such as Boston Scientific and Johnson & Johnson--after they purchase one of those startups. Story

> DePuy Orthopaedics has said patients fitted with faulty hip replacements must hand over the faulty hip device and related medical records if the medical devices company is to pay for repair surgery. Report

> National health reform may be a boon for hospitals, insurance companies and even drug makers, as millions of Americans gain medical coverage, but medical device makers in Michigan and elsewhere fear it will devastate their bottom line. Article

> A Twin Cities medical-device company is moving into new digs after winning $7.5 million in government grants. Come Nov. 1, Twin Star Medical will occupy about 4,000 square feet of space at the Excelen Center for Bone & Joint Research and Education. News

And Finally... In an early step toward letting severely paralyzed people speak with their thoughts, University of Utah researchers translated brain signals into words using two grids of 16 microelectrodes implanted beneath the skull but atop the brain. Report

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.